Teva Pharmaceutical Industries needs to clarify its intentions regarding local generic drugmaker Mylan, Mylan’s executive chairman said late Monday.
“It is time for Teva and its board to stop playing games with our company, its business, mission and strategy and its stakeholders,” Robert Coury wrote in a letter to Teva CEO Erez Vigodman.
In April, Teva offered to buy Mylan for $82 a share, or approximately $40 billion. Mylan rejected the offer and instead is trying to acquire over-the-counter drugmaker Perrigo, which has rejected Mylan’s advances.
Mr. Coury said that since Teva made its unsolicited, “non-binding expression of interest … there still is no clarity on whether or not Teva will make an actual offer to acquire Mylan and, if so, the timing, terms or conditions thereof.”
The lack of clarity is unfair to Mylan’s shareholders, who will be asked to approve a deal with Perrigo at a special meeting early in the third quarter, the letter stated.
“Teva and its board must stop pursuing what amounts to nothing more than an illusory alternative for our shareholders to the Perrigo transaction (as there is no formal offer or clear path to completion for a Teva transaction.)”
Read More
Teva recently acquired a 1.35 percent stake in Mylan, which Teva has said demonstrated its commitment to completing the Mylan takeover.
In his letter, Mr. Coury contended the stake violated U.S. antitrust laws.
Teva, based in Israel, didn’t immediately respond to a request for comment.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.